Literature DB >> 15339861

Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.

Uwe Christians1, Sven Gottschalk, Jelena Miljus, Carsten Hainz, Leslie Z Benet, Dieter Leibfritz, Natalie Serkova.   

Abstract

Co-administration of the calcineurin inhibitor cyclosporine and the mTOR inhibitors sirolimus or everolimus increases the efficacy of immunosuppression after organ transplantation. However, clinical studies showed enhancement of cyclosporine toxicity. To characterize the biochemical mechanisms involved, we assessed the time-dependent effects of cyclosporine in combination with mTOR inhibitors on energy production (ex vivo (31)P-MRS), glucose metabolism (ex vivo (13)C-MRS), and reactive oxygen species (ROS) formation (using the fluorescent agent 2',7'-dichlorofluorescein diacetate) in perfused rat brain slices. Cyclosporine alone inhibited energy production (ATP: 75+/-9%), the Krebs cycle (4-(13)C-glutamate from 1-(13)C-glucose: 61+/-27%), and oxidative phosphorylation (NAD(+): 62+/-25%) after 4 h of perfusion. After 10 h, activation of anaerobic glycolysis (3-(13)C-lactate: 140+/-17%) compensated for inhibition of mitochondrial energy production and lowered the intracellular pH. ROS formation was increased after 4 h (285+/-55% of untreated control), but not after 10 h. mTOR inhibitors alone inhibited lactate production. When combined with cyclosporine, sirolimus enhanced cyclosporine-induced inhibition of energy metabolism (ATP: 64+/-9%) and ROS formation (367+/-46%). Most importantly, sirolimus inhibited cytosolic glycolysis and therefore compensation for cyclosporine-induced ATP reduction after 10 h. In contrast to sirolimus, everolimus antagonized cyclosporine-induced inhibition of mitochondrial energy metabolism (ATP: 91+/-7%) and ROS formation (170+/-49%). The antioxidant tocopherol antagonized all cyclosporine effects on cell metabolism. Cyclosporine time-dependently inhibited mitochondrial metabolism and increased ROS, followed by compensation involving anaerobic glycolysis. Everolimus antagonized cyclosporine-induced mitochondrial dysfunction, whereas sirolimus inhibited compensatory anaerobic glycolysis, thus enhancing cyclosporine's negative effects. ROS play the key role in mediating the negative effects of cyclosporine on cell energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339861      PMCID: PMC1575349          DOI: 10.1038/sj.bjp.0705939

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

Review 1.  mTOR inhibitors: an overview.

Authors:  P Neuhaus; J Klupp; J M Langrehr
Journal:  Liver Transpl       Date:  2001-06       Impact factor: 5.799

2.  Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.

Authors:  S Bai; L J Brunner; S M Stepkowski; K L Napoli; B D Kahan
Journal:  Transplantation       Date:  2001-06-15       Impact factor: 4.939

3.  Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.

Authors:  Hemangshu Podder; Stanislaw M Stepkowski; Kimberly L Napoli; James Clark; Regina R Verani; Ting-Chao Chou; Barry D Kahan
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

Review 4.  Neurotoxicity of calcineurin inhibitors: impact and clinical management.

Authors:  W O Bechstein
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

5.  Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cells.

Authors:  F Cruz; A Wolf
Journal:  Biochem Pharmacol       Date:  2001-07-01       Impact factor: 5.858

Review 6.  Neurotoxicity of immunosuppressive drugs.

Authors:  E F Wijdicks
Journal:  Liver Transpl       Date:  2001-11       Impact factor: 5.799

7.  Median effect analysis of efficacy versus adverse effects of immunosuppressants.

Authors:  B D Kahan; W G Kramer
Journal:  Clin Pharmacol Ther       Date:  2001-07       Impact factor: 6.875

8.  Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

Authors:  N Serkova; W Jacobsen; C U Niemann; L Litt; L Z Benet; D Leibfritz; U Christians
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

9.  Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.

Authors:  J M Kovarik; B D Kahan; B Kaplan; M Lorber; M Winkler; M Rouilly; C Gerbeau; N Cambon; R Boger; C Rordorf
Journal:  Clin Pharmacol Ther       Date:  2001-01       Impact factor: 6.875

10.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

Authors:  B D Kahan
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

View more
  20 in total

Review 1.  Mechanisms of noise-induced hearing loss indicate multiple methods of prevention.

Authors:  Colleen G Le Prell; Daisuke Yamashita; Shujiro B Minami; Tatsuya Yamasoba; Josef M Miller
Journal:  Hear Res       Date:  2006-12-04       Impact factor: 3.208

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

3.  Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Authors:  Jelena Klawitter; Jost Klawitter; Volker Schmitz; Nina Brunner; Amanda Crunk; Kyler Corby; Jamie Bendrick-Peart; Dieter Leibfritz; Charles L Edelstein; Joshua M Thurman; Uwe Christians
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

Review 4.  Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.

Authors:  Patrick J Ronan; Sarah A Flynn; Thomas P Beresford
Journal:  Prog Mol Biol Transl Sci       Date:  2019-08-12       Impact factor: 3.622

5.  Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.

Authors:  Jelena Klawitter; Sven Gottschalk; Carsten Hainz; Dieter Leibfritz; Uwe Christians; Natalie J Serkova
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

6.  Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose.

Authors:  Jost Klawitter; Manuel Haschke; Christine Kahle; Colleen Dingmann; Jelena Klawitter; Dieter Leibfritz; Uwe Christians
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

7.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

Review 8.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

9.  Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal Death.

Authors:  Atsushi Mizuma; Jong Youl Kim; Rachid Kacimi; Ken Stauderman; Michael Dunn; Sudarshan Hebbar; Midori A Yenari
Journal:  J Neurotrauma       Date:  2018-12-04       Impact factor: 5.269

10.  Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.

Authors:  Jost Klawitter; Jamie Bendrick-Peart; Birgit Rudolph; Virginia Beckey; Jelena Klawitter; Manuel Haschke; Christopher Rivard; Laurence Chan; Dieter Leibfritz; Uwe Christians; Volker Schmitz
Journal:  Chem Res Toxicol       Date:  2009-01       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.